Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase III Evaluation of Docetaxel (NSC 628503) and Gemcitabine (NSC 613327) Plus G-CSF With Bevacizumab (NSC 704865, IND 7921) Versus Docetaxel (NSC 628503) and Gemcitabine (NSC 613327) Plus G-CSF With Placebo in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus

Next Previous
Search
Trial Profile

A Randomized Phase III Evaluation of Docetaxel (NSC 628503) and Gemcitabine (NSC 613327) Plus G-CSF With Bevacizumab (NSC 704865, IND 7921) Versus Docetaxel (NSC 628503) and Gemcitabine (NSC 613327) Plus G-CSF With Placebo in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Docetaxel; Filgrastim; Gemcitabine; Pegfilgrastim
  • Indications Leiomyosarcoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 26 Apr 2013 New source identified and integrated (M.D. Anderson Cancer Center; GOG0250).
    • 14 Jan 2013 New source identified and integrated (Mayo Clinic, 10-000042).
    • 27 Dec 2012 Planned end date changed from 1 Jan 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top